ANIDULAFUNGIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C58H73N7O17
Molecular Weight	1140.2369
Optical Activity	UNSPECIFIED
Defined Stereocenters	15 / 15
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12C[C@@H](O)CN1C(=O)[C@@]([H])(NC(=O)[C@H](C[C@@H](O)[C@@H](O)NC(=O)[C@]3([H])[C@@H](O)[C@@H](C)CN3C(=O)[C@@]([H])(NC(=O)[C@@]([H])(NC2=O)[C@H](O)[C@@H](O)C4=CC=C(O)C=C4)[C@@H](C)O)NC(=O)C5=CC=C(C=C5)C6=CC=C(C=C6)C7=CC=C(OCCCCC)C=C7)[C@@H](C)O

InChI

InChIKey=JHVAMHSQVVQIOT-MFAJLEFUSA-N

InChI=1S/C58H73N7O17/c1-5-6-7-24-82-40-22-18-35(19-23-40)33-10-8-32(9-11-33)34-12-14-37(15-13-34)51(74)59-41-26-43(70)54(77)63-56(79)47-48(71)29(2)27-65(47)58(81)45(31(4)67)61-55(78)46(50(73)49(72)36-16-20-38(68)21-17-36)62-53(76)42-25-39(69)28-64(42)57(80)44(30(3)66)60-52(41)75/h8-23,29-31,39,41-50,54,66-73,77H,5-7,24-28H2,1-4H3,(H,59,74)(H,60,75)(H,61,78)(H,62,76)(H,63,79)/t29-,30+,31+,39+,41-,42-,43+,44-,45-,46-,47-,48-,49-,50-,54+/m0/s1

HIDE SMILES / InChI

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf

Anidulafungin (brand names Eraxis (in U.S. and Russia) and Ecalta (in Europe)) is a semi-synthetic echinocandin with antifungal activity and it is active in vitro against many Candida, as well as some Aspergillus. Like other echinocandins, anidulafungin is not active against Cryptococcus neoformans, Trichosporon, Fusarium, or zygomycetes. This drug is indicated for the treatment of candidemia and the following Candida infections: intra-abdominal abscess and peritonitis; and for the treatment of esophageal candidiasis. Anidulafungin inhibits glucan synthase, an enzyme present in fungal, but not mammalian cells. This results in inhibition of the formation of 1,3--D-glucan, an essential component of the fungal cell wall.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
1,3-beta-glucan synthase 7 Target ID: CHEMBL2364673 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18473501	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Candidemia 3 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf	Curative		Approved 8429	ERAXIS Approved Use ERAXIS is indicated for use in adults for the treatment of the following fungal infections listed below. Specimens for fungal culture and other relevant laboratory studies (including histopathology) should be obtained prior to therapy to isolate and identify causative organism(s). Therapy may be instituted before the results of the cultures and other laboratory studies known. However, once these results become available, antifungal therapy should be adjusted accordingly. Anidulafungin is an echinocandin antifungal drug indicated in adults for the treatment of: Candidemia and other forms of Candida infections (intra-abdominal abscess and peritonitis) (1.1) Esophageal candidiasis (1.2) Limitations of use: has not been studied in endocarditis, osteomyelitis and meningitis due to Candida or in sufficient numbers of neutropenic patients (1.3) 1.1 Candidemia and Other Forms of Candida Infections (Intra-abdominal Abscess and Peritonitis) ERAXIS is indicated for the treatment of candidemia and the following Candida infections: intra-abdominal abscess and peritonitis [see Clinical Studies(14.1) and Clinical Pharmacology, Microbiology (12.4) Launch Date 1.14013438E12
Esophageal candidiasis 9 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf	Curative		Approved 8429	ERAXIS Approved Use ERAXIS is indicated for use in adults for the treatment of the following fungal infections listed below. Specimens for fungal culture and other relevant laboratory studies (including histopathology) should be obtained prior to therapy to isolate and identify causative organism(s). Therapy may be instituted before the results of the cultures and other laboratory studies known. However, once these results become available, antifungal therapy should be adjusted accordingly. Anidulafungin is an echinocandin antifungal drug indicated in adults for the treatment of: Candidemia and other forms of Candida infections (intra-abdominal abscess and peritonitis) (1.1) Esophageal candidiasis (1.2) Limitations of use: has not been studied in endocarditis, osteomyelitis and meningitis due to Candida or in sufficient numbers of neutropenic patients (1.3) 1.1 Candidemia and Other Forms of Candida Infections (Intra-abdominal Abscess and Peritonitis) ERAXIS is indicated for the treatment of candidemia and the following Candida infections: intra-abdominal abscess and peritonitis [see Clinical Studies(14.1) and Clinical Pharmacology, Microbiology (12.4) Launch Date 1.14013438E12

C_max

Value	Dose	Co-administered	Analyte	Population
7.2 mg/L DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf	200 mg 1 times / day steady-state, intravenous dose: 200 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered:		ANIDULAFUNGIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4.2 mg/L DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf	100 mg 1 times / day steady-state, intravenous dose: 100 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered:		ANIDULAFUNGIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
110.3 mg × h/L DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf	200 mg 1 times / day steady-state, intravenous dose: 200 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered:		ANIDULAFUNGIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
55.2 mg × h/L DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf	100 mg 1 times / day steady-state, intravenous dose: 100 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered:		ANIDULAFUNGIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
26.5 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf	200 mg 1 times / day steady-state, intravenous dose: 200 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered:		ANIDULAFUNGIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
26.5 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf	100 mg 1 times / day steady-state, intravenous dose: 100 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered:		ANIDULAFUNGIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
1% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf	200 mg 1 times / day steady-state, intravenous dose: 200 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered:		ANIDULAFUNGIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf	100 mg 1 times / day steady-state, intravenous dose: 100 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered:		ANIDULAFUNGIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
200 mg 1 times / day multiple, intravenous Recommended Dose: 200 mg, 1 times / day Route: intravenous Route: multiple Dose: 200 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf Page: p.4	unhealthy, 16-89 n = 127 Health Status: unhealthy Condition: Candida infections\|Candidemia Age Group: 16-89 Sex: M+F Population Size: 127 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf Page: p.4	Disc. AE: Multi-organ failure... AEs leading to discontinuation/dose reduction: Multi-organ failure Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf Page: p.4
200 mg 1 times / day multiple, intravenous Recommended Dose: 200 mg, 1 times / day Route: intravenous Route: multiple Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/23676114 Page: p.4	unhealthy, 56.5 (± 18.5) n = 43 Health Status: unhealthy Condition: Candidemia Age Group: 56.5 (± 18.5) Sex: M+F Population Size: 43 Sources: https://pubmed.ncbi.nlm.nih.gov/23676114 Page: p.4	Disc. AE: Drug hypersensitivity, Skin rash... AEs leading to discontinuation/dose reduction: Drug hypersensitivity (2.3%) Skin rash (2.3%) Sources: https://pubmed.ncbi.nlm.nih.gov/23676114 Page: p.4
400 mg single, intravenous Overdose Dose: 400 mg Route: intravenous Route: single Dose: 400 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf Page: p.9	unhealthy Health Status: unhealthy Condition: Candida infections\|Candidemia Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf Page: p.9	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf Page: p.9
200 mg 1 times / day multiple, intravenous Recommended Dose: 200 mg, 1 times / day Route: intravenous Route: multiple Dose: 200 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Candida infections\|Candidemia Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf Page: p.1	Disc. AE: Abnormal liver function tests, Hepatitis... AEs leading to discontinuation/dose reduction: Abnormal liver function tests Hepatitis Hepatic failure Hypersensitivity Anaphylaxis Rash Urticaria Flushing Pruritus Bronchospasm Dyspnea Hypotension Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf Page: p.1

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1587	inhibitor 1767	inhibitor 1852

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP 111 CYP1A2 1524 CYP2A6 707 CYP2C19 1478 CYP2E1 882 P-gp 1461 BCRP 699	P-gp 1537 CYP 270	CYP 76

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
P-gp 1650	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 54.0	inconclusive
CYP 147	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 54.0	no
CYP 147	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 54.0	no
CYP2E1 970	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 44.0	no
CYP1A2 1692	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 44.0	no	no (co-administration study) Comment: rifampin did not significantly alter anidulafungin pharmacokinetics Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 44.0
CYP2A6 739	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 44.0	no	no (co-administration study) Comment: rifampin did not significantly alter anidulafungin pharmacokinetics Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 44.0
CYP2C19 1553	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 44.0	no	no (co-administration study) Comment: voriconazole did not significantly alter anidulafungin pharmacokinetics Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 44.0
CYP2C9 1819	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 44.0	no	no (co-administration study) Comment: voriconazole did not significantly alter anidulafungin pharmacokinetics; rifampin did not significantly alter anidulafungin pharmacokinetics Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 44.0
CYP2D6 1891	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 44.0	no	no (co-administration study) Comment: rifampin did not significantly alter anidulafungin pharmacokinetics Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 44.0
CYP3A4 1925	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 44.0	no	no (co-administration study) Comment: cyclosporine did not significantly alter anidulafungin pharmacokinetics; voriconazole did not significantly alter anidulafungin pharmacokinetics; rifampin did not significantly alter anidulafungin pharmacokinetics Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 44.0
BCRP 773	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/27001813/	strong [IC50 7 uM]

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 1537	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 54.0	inconclusive
CYP 270	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 44, 54	no		no (co-administration study) Comment: rifampin did not significantly alter anidulafungin pharmacokinetics Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 44, 54

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:55346	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:55346
ChemicalBook	CB71120054	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB71120054
MolPort	MolPort-006-167-527	https://www.molport.com/shop/molecule-link/MolPort-006-167-527
eMolecules	36905381	https://www.emolecules.com/cgi-bin/more?vid=36905381

PubMed

Title	Date	PubMed
The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications.	2006	17047411
Anidulafungin: a new echinocandin for the treatment of fungal infections.	2006 Aug	16969430
Voriconazole in the management of nosocomial invasive fungal infections.	2006 Jun	18360588
Gateways to clinical trials.	2006 May	16801985
Another option for fungal infections.	2006 May-Jun	16906658
The safety of anidulafungin.	2006 Nov	17044802
Echinocandins in the management of invasive fungal infections, Part 2.	2006 Oct 1	16990627
Gateways to clinical trials.	2006 Sep	17003851
Echinocandins for candidemia in adults without neutropenia.	2006 Sep 14	16971721
Echinocandins in the management of invasive fungal infections, part 1.	2006 Sep 15	16960253
Antifungal agents in neonates: issues and recommendations.	2007	17927303
Role of micafungin in the antifungal armamentarium.	2007	17504145
Anidulafungin--state of affairs from a clinical perspective.	2007	17394608
Fungal infections of the CNS: treatment strategies for the immunocompromised patient.	2007	17381184
Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment.	2007 Apr	17389555
Role of posaconazole in the management of oropharyngeal and esophageal candidiasis.	2007 Aug	18472974
One year prospective survey of Candida bloodstream infections in Scotland.	2007 Aug	17644714
A review of the new antifungals: posaconazole, micafungin, and anidulafungin.	2007 Dec	18189069
[In vitro activity of amphotericin B and anidulafungin against Candida spp. biofilms].	2007 Dec 31	18095759
New drugs 07, part I.	2007 Feb	17273084
Anidulafungin: a new echinocandin for candidal infections.	2007 Feb	17266452
A comparative evaluation of properties and clinical efficacy of the echinocandins.	2007 Jul	17661730
Nongastroesophageal reflux disease-related infectious, inflammatory and injurious disorders of the esophagus.	2007 Jul	17545784
Development of anidulafungin for disk diffusion susceptibility testing against Candida spp.	2007 Jul	17376633
Update on new antifungal therapy.	2007 Jul-Sep	18019516
Echinocandins--first-choice or first-line therapy for invasive candidiasis?	2007 Jun 14	17568034
Anidulafungin versus fluconazole for invasive candidiasis.	2007 Jun 14	17568028
Comparison of echinocandin antifungals.	2007 Mar	18360617
Essential gene identification and drug target prioritization in Aspergillus fumigatus.	2007 Mar	17352532
Lack of pharmacokinetic interaction between anidulafungin and tacrolimus.	2007 Mar	17322142
The echinocandins.	2007 Mar	17316149
Antifungal drug discovery, six new molecules patented after 10 years of feast: why do we need new patented drugs apart from new strategies?	2007 Nov	18221175
Mould breakthrough in immunosuppressed adults receiving anidulafungin: a report of 2 cases.	2007 Nov	17900699
Management of invasive pulmonary aspergillosis in non-neutropenic critically ill patients.	2007 Oct	17646966
Recent advances in antifungal agents.	2007 Sep	17897080
Susceptibility patterns of Candida species recovered from Canadian intensive care units.	2007 Sep	17869976
Anidulafungin and fluconazole for candidiasis.	2007 Sep 27	17902202
Anidulafungin and fluconazole for candidiasis.	2007 Sep 27	17898107
Bench-to-bedside review: Candida infections in the intensive care unit.	2008	18279532
Advances in antifungal therapy.	2008	17967129
Stimulation of chitin synthesis rescues Candida albicans from echinocandins.	2008 Apr 4	18389063
In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.	2008 Aug	18458136
Management of Candida infections in the adult intensive care unit.	2008 Feb	18201143
In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.	2008 Feb	18070979
Paradoxical growth effects of the echinocandins caspofungin and micafungin, but not of anidulafungin, on clinical isolates of Candida albicans and C. dubliniensis.	2008 Feb	18057972
Early clinical experience with anidulafungin at a large tertiary care medical center.	2008 Jan	18154476
Propofol lipidic infusion promotes resistance to antifungals by reducing drug input into the fungal cell.	2008 Jan 17	18201378
Anidulafungin was noninferior to fluconazole for invasive candidiasis.	2008 Jan-Feb	18171002
[Anidulafungin in the invasive fungal infection: current topics].	2008 Jun	18473499
Liposomal amphotericin B: what is its role in 2008?	2008 May	18430132

Patents

Sample Use Guides

In Vivo Use Guide

Candidemia and other Candida infections (intra-abdominal abscess, and peritonitis) The recommended dose is a single 200 mg loading dose on Day 1, followed by 100 mg daily dose thereafter. Duration of treatment should be based on the patient’s clinical response. In general, antifungal therapy should continue for at least 14 days after the last positive culture. Esophageal Candidiasis: The recommended dose is a single 100 mg loading dose on Day 1, followed by 50 mg daily dose thereafter. Patients should be treated for a minimum of 14 days and for at least 7 days following resolution of symptoms. Duration of treatment should be based on the patient’s clinical response. Because of the risk of relapse of esophageal candidiasis in patients with HIV infections, suppressive antifungal therapy may be considered after a course of treatment.

Route of Administration: Intravenous

In Vitro Use Guide

A 48 hours exposure of human erythrocytes to Anidulafungin (1.5 - 6 µg/ml) significantly increased hemolysis and the percentage of annexin-V-binding cells, and significantly decreased forward scatter. Anidulafungin (6 µg/ml) slightly, but significantly inceased Fluo3-fluorescence and the effect of Anidulafungin on annexin-V-binding was slightly, but significantly blunted by removal of extracellular Ca2+. The effect of Anidulafungin on annexin-V-binding was further significantly blunted by the p38 kinase inhibitor SB203580 (2 µM) and NO donor nitroprusside (1 µM). An increase of extracellular K+ concentration significantly blunted the effect of Anidulafungin on cell volume but not on annexin-V-binding.

Name

Type

Language

ANIDULAFUNGIN

Official Name

English

VER002

Code

English

LY-303366

Code

English

ANIDULAFUNGIN [ORANGE BOOK]

Common Name

English

Anidulafungin [WHO-DD]

Common Name

English

D70013

Code

English

ANIDULAFUNGIN [VANDF]

Common Name

English

LY303366

Code

English

ERAXIS

Brand Name

English

ANIDULAFUNGIN [USAN]

Common Name

English

ECHINOCANDIN B, 1-((4R,5R)-4,5-DIHYDROXY-N(SUP 2)-((4''-(PENTYLOXY)(1,1':4',1''-TERPHENYL)-4-YL)CARBONYL)-L-ORNITHINE)-

Common Name

English

V-ECHINOCANDIN

Common Name

English

(4R,5R)-4,5-DIHYDROXY-N(SUP 2)-((4''-(PENTYLOXY)-P-TERPHENYL-4-YL)CARBONYL)-L-ORNITHYL-L-THREONYL-TRANS-4-HYDROXY-L-PROLYL-(S)-4-HYDROXY-4-(P-HYDROXYPHENYL)-L-THREONYL-L-THREONYL-(3S,4S)-3-HYDROXY-4-METHYL-L-PROLINE CYCLIC (6->1)-PEPTIDE

Common Name

English

VER-002

Code

English

ANIDULAFUNGIN [MART.]

Common Name

English

ANIDULAFUNGIN [EMA EPAR]

Common Name

English

D-70013

Code

English

anidulafungin [INN]

Common Name

English

ANIDULAFUNGIN [MI]

Common Name

English

Classification Tree Code System Code

LIVERTOX

58